described that the Nrf2/Keap1 redox pathway is dysfunctional in diabetics and contributes to the delayed wound healing phenotype. We engineered a self-assembling lipoproteoplex, with Keap1 siRNA to aid in the restoration of Nrf2 and to enhance the rate of diabetic wound healing.
METHODS:
We designed a novel formulation of DOTAP Sodium Cholate and a super-charged protein, which was used to package siRNA and then applied to standardized wounds on diabetic mice. Wound beds were collected at several time points for analysis of tissue histology and gene expression. Rate of wound closure was calculated using photometric analysis.
RESULTS:
In the wound bed, Keap1 siRNA treated mice decreased Keap1 gene expression (55.4 ± 22.9%; p=0.004) and protein expression (94 ± 0.42%; p=0.038) compared to controls. Downstream protein expression of Nrf2 increased (3.27 ± 1.63 fold; p=0.039). The expression of antioxidant genes, NQO-1 and MnSOD-1 increased (4.99 ± 0.1 fold; p=0.04 and 3.66 ± 0.2 fold; p=0.01, respectively). The expression of the chemokine, SDF-1 increased (7.51 ± 0.12 fold; p=0.01). Additionally, the expression of EGF increased (6.48 ± 0.15 fold; p=0.005). At day 10, the epithelial gap of Keap1 treated mice decreased compared to control mice (3.95 ± 0.21 mm vs 8.07 ± 1.37mm; p=0.004), granulation tissue increased (2.15 ± 0.65 mm 2 vs 1.15 ± 0.44 mm 2 ; p= 0.049), and CD31+ cells/hpf increased (109.8 ± 17.96 vs 71.2 ± 27.32; p=0.02). Keap1 siRNA treated mice resulted in accelerated time to wound closure (22.3 ± 1.974 days vs 31 days; p=0.0213). Wound burden was decreased markedly by 57% compared to controls.
CONCLUSIONS:
Our novel formulated drug vehicle effectively delivered siRNA to the wound bed and resulted in a clinically relevant acceleration of wound healing. Acceleration was accomplished through downstream changes in redox homeostasis, growth factors, and blood vessel formation. This novel therapy could be rapidly translated for clinical use. We have previously implicated dysfunction of the Nrf2/ Keap1 anti-oxidant pathway in this pathology, but the relative contribution of Nrf2 to physiologic and diabetic wound healing remains unknown.
METHODS:
Excisional wounds were created in the dorsum of wild-type, diabetic, Nrf2-/-, and Nrf2+/-mice, and stented to prevent secondary contraction. Wound tissue was analyzed for oxidative damage (8-OhdG), gene expression, and re-epithelialization (epithelial gap).
RESULTS:
Oxidative damage was greater in both diabetic (2.8 ng/mL) and Nrf2-/-(2.5 ng/mL) skin postwounding as compared to wild-type (1.1 ng/mL) or Nrf2+/-(1.8 ng/mL, p<.05). Intact skin of diabetic mice had 20% lower levels of Nrf2 gene expression relative to wild-type, and the differences persisted post-wounding (day 5: 27% day 7: 58%). Nrf2+/-mice had intermediate expression levels (day 5: 60%, p<.02, day 7: 76%). Keap1, the physiologic repressor of Nrf2, was overexpressed in diabetic mice as compared to wildtype (intact: 171%, day 5: 253%, day 7: 118%) while it remained constant or decreased in Nrf2-/-mice (intact: 103%, day 5: 61%, day 7: 107%). Gene expression of NAD(P)H quinone dehydrogenase (NQO-1), an antioxidant enzyme activated by Nrf2, peaked later in diabetic (day 10) and Nrf2-/-(day 7) mice compared to wild-type and Nrf2+/-mice (day 5). NQO-1 was also decreased in both diabetic and Nrf2 -/-intact (2% and 30%, respectively p<.05) and wounded tissue (11% and 8%, respectively p<.05) as compared to wild-type, while Nrf2+/-displayed an intermediate phenotype (intact: 37%). At day 7 post-wounding, diabetic and Nrf2+/-wounds displayed the largest epithelial gap (9.7mm and 7.6mm, respectively). Wild-type mice had the smallest epithelial gap (4.1mm), while Nrf2-/-mice displayed an intermediate phenotype (7.0mm).
CONCLUSION:
Here, we demonstrate the role of Keap1-mediated Nrf2 loss in impaired diabetic redox handling and wound-healing in an animal model. Our findings further validate this pathway as a promising target for therapies aimed at improving both diabetic and physiologic wound healing.
